Revolution Medicines enters September with the analyst re-rating from last week holding firm — and the short position that greeted those upgrades continuing to shrink, even as the stock has given back a fraction of its gains.
The Street's conviction has only grown since the August 27 wave of target hikes. Needham raised its target to $275 on August 31, and UBS followed with a lift to $265 on August 28 — both maintaining Buy. Combined with the six firms that moved the week prior, the consensus mean target has climbed to $248.77 against a current price of $209.87, implying roughly 18.5% upside. Every firm that moved kept a positive rating. The outlier remains Bernstein, which raised its target to $179 but held at Market Perform — well below the pack, and the only cautious voice in a crowd of bulls. The bull case rests on RVMD's differentiated RAS(ON) inhibitor platform and a large addressable market in precision oncology. The bear case — competition from better-resourced pharma players and an efficacy profile still being established against existing treatments — has not shifted analyst sentiment materially, but it is worth noting that the stock's 161% year-to-date run means the bar for further re-rating is rising.
Short positioning has moved decisively in the same direction as the analysts. SI has fallen nearly 10% on the week and is down 30% over the past month, dropping from roughly 14.2 million shares in late July to approximately 9.5 million now, representing about 4.9% of free float. That is a meaningful compression. The borrow market reflects no tension at all: availability is at 6,622% — essentially unlimited supply relative to what is borrowed — and cost to borrow has eased 25% on the week to just 0.47%. There is no squeeze pressure, no scramble for shares. Shorts are leaving on their own terms, not being forced out. The ORTEX short score has drifted down to 40.2 from 42.5 a week ago, consistent with a position that is unwinding rather than building.
Options have normalised after last week's dramatic call-skew spike. The put/call ratio is back near its 20-day average at 0.77, roughly in line with the 0.776 mean — a stark contrast to the sub-0.52 reading that defined the August 26 note. That extreme has faded. Options traders are no longer pricing in the kind of aggressive near-term upside they were reaching for last week; the PCR z-score of -0.63 suggests positioning is mildly call-heavy but not at an extreme in either direction. The setup has normalised, not reversed.
Insider activity is the week's one signal that cuts against the bullish grain — though its significance is tempered by how it was executed. Director Kim Lorence H. sold approximately 55,800 shares on August 31 across multiple tranches, totalling roughly $11.4 million. Every transaction was conducted under a pre-arranged 10b5-1 plan, meaning the sales were scheduled in advance and carry far less informational weight than a discretionary open-market sale. CEO Mark Goldsmith also sold small lots on August 21 under the same structure. The 90-day net insider position is -$41.3 million, but that figure is dominated by plan-driven disposals into a stock that has risen sharply year-to-date. Institutional holders tell a different story: BlackRock added 2.5 million shares in July, Fidelity added 3.5 million, and Baker Bros. added 1.9 million — all filing after the most recent available dates. Darwin Global built a new 4.96% stake in Q2. The institutional flow is broadly supportive.
The next earnings event lands on November 5. After the last two prints, RVMD gained 4.6% and 2.2% on the day, with five-day moves of 3.0% and 6.1% respectively — a consistent pattern of positive reactions. With the stock having already run hard into those results on clinical optimism, the question heading into Q3 will be whether pipeline data updates between now and then reset expectations higher again, or whether the current valuation — price-to-book near 38x on a pre-profitability biotech — begins to attract more scrutiny from the one firm already sitting on the sidelines.
See the live data behind this article on ORTEX.
Open RVMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
